U.S. Funds Early Ibogaine PTSD Research, Citing Veterans' Demand

Health Secretary Robert F. Kennedy Jr. on Thursday announced up to $4.9 million in federal funding to jump-start U.S. research preparations on the psychedelic drug ibogaine as a potential treatment for post-traumatic stress disorder, with the effort centered on veterans and run in partnership with the Department of Veterans Affairs.^[1]

Speaking at an afternoon briefing in Washington, Kennedy said the money will finance work on ibogaine manufacturing, dosing, and study design rather than immediate patient trials, describing it as a "groundwork phase" to ensure any later clinical studies meet strict safety and regulatory standards.^[1] Veterans Affairs Secretary Doug Collins said the VA will formally partner on the project and stressed that no ibogaine would be offered to patients outside monitored studies, calling the approach "veteran-driven but science-led."^[1]

A key piece of the plan involves tapping data from Beond Inc., a Texas-based company that has provided ibogaine treatments to more than 3,000 people at clinics in Mexico, including many U.S. veterans who traveled there seeking relief from PTSD and addiction.^[1] U.S. officials say that real-world experience will be used to inform dose ranges, screening protocols, and safety measures as they design formal trials that could eventually take place under Food and Drug Administration oversight.^[1]

The move stems from an April 2026 executive order in which President Donald Trump directed health and veterans agencies to speed up research into psychedelic therapies that show "credible potential benefit" for conditions like PTSD, depression and substance use disorders among service members.^[1] In the months since, veteran advocacy groups have lobbied for ibogaine to be included alongside better-known compounds like MDMA and psilocybin, arguing that many former service members are already seeking the drug abroad and deserve regulated options at home.^[1]

Officials on Thursday framed the ibogaine initiative as a response to that grassroots pressure but also as a test of whether the federal government can build a rigorous evidence base around an underground treatment without endorsing its use prematurely.^[1] Kennedy said the initial $4.9 million is meant to de-risk the early stages of research so that larger clinical trials, if warranted, can move faster and with clearer safety guardrails, while Collins emphasized that the VA will not recommend ibogaine until those trials show both effectiveness and acceptable cardiac and psychological risk profiles.^[1]

1. PBS News